UBS Group’s OCATA THERAPEUTICS, INC. COMMON STOCK OCAT Stock Holding History

UBS Group’s Portfolio OCAT Stock Details OCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-544,129	Closed	-$4.58M	–	8746
2015 Q4	$4.58M	Buy	544,129 +527,341	+3,141%	+$3.53M	﹤0.01%	2042
2015 Q3	$70K	Buy	16,788 +12	+0.1%	+$52	﹤0.01%	5524
2015 Q2	$88K	Buy	16,776 +12,740	+316%	+$81.6K	﹤0.01%	5516
2015 Q1	$25K	Buy	+4,036	New	+$25.8K	﹤0.01%	6767

UBS Group's OCAT Position: Q1 2016 in Review

UBS Group sold out of OCATA THERAPEUTICS, INC. COMMON STOCK (OCAT) in Q1 2016, closing a stake of 544,129 shares — an estimated $4.58M sold.

UBS Group first reported a position in OCAT in Q1 2015 and held it in 4 quarters. The position peaked at $4.58M in Q4 2015. 1 fund tracked by Wall St. Rank holds OCAT as of Q1 2016.

UBS Group reported no remaining OCATA THERAPEUTICS, INC. COMMON STOCK position as of Q1 2016 after selling out during the quarter.
UBS Group sold 544,129 OCATA THERAPEUTICS, INC. COMMON STOCK shares in Q1 2016, an estimated $4.58M.
UBS Group first reported a position in OCATA THERAPEUTICS, INC. COMMON STOCK in Q1 2015 and held it in 4 quarters.
UBS Group's OCATA THERAPEUTICS, INC. COMMON STOCK position peaked at $4.58M in Q4 2015.
1 fund tracked by Wall St. Rank held OCATA THERAPEUTICS, INC. COMMON STOCK as of Q1 2016.

Based on UBS Group's 13F filing for Q1 2016, filed 12 May 2016.